Clinical trial
A Phase II Study of PM01183 as Second-line Treatment in Patients with Metastatic Pancreatic Cancer
To evaluate the antitumor activity of PM01183 in terms of overall survival rate at 6 months (OS6) in patients with metastatic pancreatic cancer.
| Category | Value |
|---|---|
| Study start date | 2011-03-10 |